Ustekinumab:
Table of Contents
• Product comparison
• Average Sales Prices Q2 2025 & Q3 2025
• Reimbursement information for Q3 2025
• Historical ASPs
• Cumulative Average Changes of ASP
• WAC vs Initial ASPs
• Aria ASP predictive model
Aria Analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
Ustekinumab: Q3 2025 ASP Report
Product Comparison
Product
Biologic
Stelara®1 (Janssen)
Subcutaneous Injection
Injection: Single-dose prefilled syringe 45 mg/0.5 mL or 90 mg/mL
Injection: single dose vial 45mg/0.5mL
Intravenous Infusion
Injection: Single dose vial 130mg/26mL
Biosimilars
Otulfi®2 (Fresenius Kabi)
Wezlana®3 (Amgen)
Pyzchiva®4 (Sandoz)
Yesintek®5 (Biocon)
Selarsdi®6 (Teva)
Steqeyma®7 (Celltrion)
Subcutaneous Injection
Injection: Single-dose prefilled syringe 45 mg/0.5 mL or 90 mg/mL
Intravenous Infusion
Injection: Single dose vial 130mg/26mL
Subcutaneous Injection
Injection: Single-dose prefilled syringe 45 mg/0.5 mL or 90 mg/mL
Injection: single dose vial 45mg/0.5mL
Intravenous Infusion
Injection: Single dose vial 130mg/26mL
Subcutaneous Injection
Injection: Single-dose prefilled syringe 45 mg/0.5 mL or 90 mg/mL
Intravenous Infusion
Injection: Single dose vial 130mg/26mL
Treat moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn’s disease, and moderately to severely active ulcerative colitis in adults; Treat moderate to severe plaque psoriasis and active psoriatic arthritis in pediatric patients 6 years and older.
Yes
Ustekinumab: Q3 2025 ASP Report
Stelara (Janssen)
Ustekinumab: Q3 2025 ASP Report
Ustekinumab: Q3 2025 ASP Report
Cumulative Average Change of ASP
This graph shows the cumulative average change in the average sales price (ASP), from the launch of the first biosimilar to every subsequent quarter's ASP. It highlights the evolution of ASPs over the products’ lifecycles and provides a concise overview of pricing dynamics through the fluctuating rate of change.
Stelara (Janssen)
Ustekinumab: Q3 2025 ASP Report
WAC* vs. Initial ASPs, Stelara IV (Janssen)
This graph highlights the ASP approach that manufacturers take at product launch, showing the first 3 ASPs that posted after the product’s release. This can provide insight into new products and how their launch strategy compares to legacy products.
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model. We’ve included this prediction to give context on the ASP trends and where we see the ASP going in the future, empowering members to make informed long-term decisions today.